BSE filing, NSE: SHUKRAPHAR. Summary written from the filing by ALFA Finder's alert engine.
Shukra Pharmaceuticals Ltd: key numbers
- Share price
- ₹71.89
- Market cap
- ₹3,181 Cr
- Revenue (annual)
- ₹56.73 Cr
- Net profit (annual)
- ₹22.06 Cr
- P/E (TTM)
- 93.6×Sector 46.1×
- Promoter holding
- 51.15%+0.19% QoQ
- FII holding
- 0.43%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Shukra Pharmaceuticals Ltd
All →Shukra Pharmaceuticals Board Meeting Date
Shukra Medtech Limited has scheduled a board meeting on November 3, 2026, to consider and approve its unaudited financial results for the quarter ended September 2026.
Shukra Pharmaceuticals Other Announcement
Shukra Medtech submitted a revised CA certificate to NSE for its name and symbol change application. The filing requests final exchange approval for the corporate rename.
Shukra Pharmaceuticals Other Announcement
Shukra Pharmaceuticals Limited has submitted the certificate under Regulation 74(5) of the SEBI (Depositories and Participants) Regulations, 2018 for the quarter ended September 30, 2026.
Shukra Pharmaceuticals Capital Structure Change
Shukra Pharmaceuticals allotted 17.35 lakh equity shares upon warrant conversion to promoters. The exercise raised Rs. 4.63 Crore, increasing the paid-up capital.
- Value
- ₹4.63 Cr
Shukra Pharmaceuticals Price Movement Clarification
Shukra Pharmaceuticals clarified that the recent share price movement is market-driven. The company confirmed no undisclosed, price-sensitive information exists.
Shukra Pharmaceuticals Annual General Meeting
Shukra Pharmaceuticals Ltd issued a corrigendum to its Postal Ballot notice regarding the proposed alteration of its Main Object Clause and name change.
Other other announcement announcements
All →Mahindra & Mahindra Financial Services Other Announcement
Mahindra & Mahindra Financial filed its ALM statement as of September 30, 2026, submitted to RBI. It is a periodic regulatory return with no new transaction.
ACME Solar Holdings Other Announcement
ACME Solar filed the CARE Ratings monitoring agency report on its Rs.2,800 crore QIP for the quarter ended 30 September 2026. The report shows no deviation from the offer objects.
eMudhra Other Announcement
eMudhra Ltd disclosed that SES ESG revised its ESG score from 68.0 to 64.9 in its ESG Report 2026. The company states it did not engage SES ESG, and the revision relates to its certificate business.
Aarti Pharmalabs Other Announcement
Aarti Pharmalabs has intimated under Regulation 46 that it revamped its website at the existing URL to improve design and accessibility. The notice has no financial or business substance.
Sagarsoft (India) Other Announcement
Sagarsoft (India) filed its Regulation 32 fund utilisation statement for its 2021 preferential issue. No deviation was reported and the full Rs.5.08 Crore was used.
Sadhana Nitro Chem Other Announcement
Sadhana Nitro Chem reported no deviation in use of its preferential issue proceeds for the quarter ended September 2026. The Audit Committee reviewed the statement.